307 related articles for article (PubMed ID: 21309961)
41. Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease.
Blesa González R; Boada Rovira M; Martínez Parra C; Gil-Saladié D; Almagro CA; Gobartt Vázquez AL;
Neurologia; 2011 Jun; 26(5):262-71. PubMed ID: 21227548
[TBL] [Abstract][Full Text] [Related]
42. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
Choi SH; Park KW; Na DL; Han HJ; Kim EJ; Shim YS; Lee JH;
Curr Med Res Opin; 2011 Jul; 27(7):1375-83. PubMed ID: 21561398
[TBL] [Abstract][Full Text] [Related]
43. Predictors of long-term treatment effect of rivastigmine in Alzheimer's disease: a role for beta-amyloid plasma levels?
Sobów T; Kłoszewska I; Flirski M; Liberski P
Neurol Neurochir Pol; 2009; 43(6):507-16. PubMed ID: 20054753
[TBL] [Abstract][Full Text] [Related]
44. Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.
Grossberg GT; Farlow MR; Meng X; Velting DM
Curr Alzheimer Res; 2015; 12(1):53-60. PubMed ID: 25523430
[TBL] [Abstract][Full Text] [Related]
45. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
46. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study.
Gauthier S; Robillard A; Cohen S; Black S; Sampalis J; Colizza D; de Takacsy F; Schecter R;
Curr Med Res Opin; 2013 Aug; 29(8):989-1000. PubMed ID: 23647369
[TBL] [Abstract][Full Text] [Related]
47. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
48. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.
Erkinjuntti T; Skoog I; Lane R; Andrews C
Int J Clin Pract; 2002 Dec; 56(10):791-6. PubMed ID: 12510954
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
Park KW; Kim EJ; Han HJ; Shim YS; Kwon JC; Ku BD; Park KH; Yi HA; Kim KK; Yang DW; Lee HW; Kang H; Kwon OD; Kim S; Lee JH; Chung EJ; Park SW; Park MY; Yoon B; Kim BC; Seo SW; Choi SH
PLoS One; 2017; 12(8):e0182123. PubMed ID: 28786987
[TBL] [Abstract][Full Text] [Related]
50. Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease.
Lee JH; Sevigny J
Alzheimer Dis Assoc Disord; 2011; 25(1):58-62. PubMed ID: 20975519
[TBL] [Abstract][Full Text] [Related]
51. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
Frölich L; Ashwood T; Nilsson J; Eckerwall G;
J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153
[TBL] [Abstract][Full Text] [Related]
52. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.
Sadowsky CH; Farlow MR; Meng X; Olin JT
Int J Clin Pract; 2010 Jan; 64(2):188-93. PubMed ID: 20089009
[TBL] [Abstract][Full Text] [Related]
53. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
54. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
Schmidt R; Alf C; Bancher C; Benke T; Berek K; Dal-Bianco P; Führwürth G; Imarhiagbe D; Jagsch C; Lechner A; Rainer M; Reisecker F; Rotaru J; Uranüs M; Walter A; Winkler A; Wuschitz A
Neuropsychiatr; 2009; 23(1):58-63. PubMed ID: 19272293
[TBL] [Abstract][Full Text] [Related]
55. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.
Nagy B; Brennan A; Brandtmüller A; Thomas SK; Sullivan SD; Akehurst R
Int J Geriatr Psychiatry; 2011 May; 26(5):483-94. PubMed ID: 20845395
[TBL] [Abstract][Full Text] [Related]
56. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
Cummings JL; Farlow MR; Meng X; Tekin S; Olin JT
Clin Drug Investig; 2010; 30(1):41-9. PubMed ID: 19995097
[TBL] [Abstract][Full Text] [Related]
57. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
Pregelj P
Psychogeriatrics; 2012 Sep; 12(3):165-71. PubMed ID: 22994614
[TBL] [Abstract][Full Text] [Related]
58. Long-term rivastigmine treatment in a routine clinical setting.
Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
[TBL] [Abstract][Full Text] [Related]
59. The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer's Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study.
Yatawara C; Zailan FZ; Chua EV; Lim LLH; Silva E; Wang JS; Ng A; Ng KP; Kandiah N
Clin Interv Aging; 2021; 16():301-309. PubMed ID: 33642856
[TBL] [Abstract][Full Text] [Related]
60. Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.
Frampton JE
Drugs Aging; 2014 Aug; 31(8):639-49. PubMed ID: 24989628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]